# OnCo record paper-andersen-conditional-approval-cancer-drugs-canada-curr-oncol-2019 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-andersen-conditional-approval-cancer-drugs-canada-curr-oncol-2019/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-andersen-conditional-approval-cancer-drugs-canada-curr-oncol-2019" ;
  schema:name "Conditional approval of cancer drugs in Canada: accountability and impact on public funding"@en ;
  schema:description "One in five cancer drugs reviewed for public funding in Canada from 2010 to 2017 had a conditional licence based on early data; none received an unconditional funding recommendation, and Health Canada never revoked a conditional licence for unmet conditions."@en ;
  schema:url <https://onco.cc/key-papers/paper-andersen-conditional-approval-cancer-drugs-canada-curr-oncol-2019/> ;
  schema:dateModified "2026-11-03"^^xsd:date ;
  schema:citation <https://doi.org/10.3747/co.26.4397>, <https://pubmed.ncbi.nlm.nih.gov/30853815/> ;
  schema:sameAs <https://doi.org/10.3747/co.26.4397> ;
  schema:datePublished "2019"^^xsd:gYear ;
  schema:author "Andersen SK, Penner N, Chambers A, et al." ;
  onco:institutions <https://onco.cc/institutions/health-canada/>, <https://onco.cc/institutions/cda-amc/> ;
  onco:journals <https://onco.cc/journals/current-oncology-mdpi/> .